Sight Sciences (SGHT) Aandelenoverzicht
Sight Sciences, Inc., een bedrijf in oogheelkundige medische apparatuur, richt zich op de ontwikkeling en commercialisering van chirurgische en niet-chirurgische technologieën voor de behandeling van oogaandoeningen in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
SGHT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sight Sciences, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$4.91 |
| 52 Week Hoogtepunt | US$9.24 |
| 52 Week Laag | US$3.11 |
| Bèta | 2.38 |
| 1 maand verandering | -13.71% |
| 3 maanden verandering | 13.66% |
| 1 Jaar Verandering | 40.69% |
| 3 jaar verandering | -44.14% |
| 5 jaar verandering | -86.72% |
| Verandering sinds IPO | -85.34% |
Recent nieuws en updates
Narratiefupdate • Jul 15
SGHT: Medtech Sector Support And Dry Eye Expansion Will Drive Measured Repricing
Analysts have adjusted their stance on Sight Sciences by moving the price target to $6.00 from $5.15, citing updated medtech sector models and a preference for higher-quality stocks during what they describe as a skittish trading backdrop. Analyst Commentary on Sight Sciences Recent commentary on Sight Sciences reflects a mixed tone.Narratiefupdate • Jul 01
SGHT: Sector Strength And Dry Eye Outlook Will Support Measured Repricing
Analysts lifted their price target on Sight Sciences to $5.15 from $4.35, citing updated medical technology sector models after Q1 reports and a view that sector fundamentals remain solid. Analyst Commentary Recent commentary on Sight Sciences reflects a mixed stance, with some analysts adjusting their models after the latest Q1 updates while keeping a neutral overall view on the stock.Recent updates
Narratiefupdate • Jul 15
SGHT: Medtech Sector Support And Dry Eye Expansion Will Drive Measured Repricing
Analysts have adjusted their stance on Sight Sciences by moving the price target to $6.00 from $5.15, citing updated medtech sector models and a preference for higher-quality stocks during what they describe as a skittish trading backdrop. Analyst Commentary on Sight Sciences Recent commentary on Sight Sciences reflects a mixed tone.Narratiefupdate • Jul 01
SGHT: Sector Strength And Dry Eye Outlook Will Support Measured Repricing
Analysts lifted their price target on Sight Sciences to $5.15 from $4.35, citing updated medical technology sector models after Q1 reports and a view that sector fundamentals remain solid. Analyst Commentary Recent commentary on Sight Sciences reflects a mixed stance, with some analysts adjusting their models after the latest Q1 updates while keeping a neutral overall view on the stock.
Narratiefupdate • Jun 17
SGHT: Sector Support And Dry Eye Execution Will Drive Future Upside
Analysts have increased their price target on Sight Sciences stock to $5.15 from $4.35, citing refreshed medical technology sector models after Q1 updates and a view that broader fundamentals in the space remain solid. Analyst Commentary on Sight Sciences Recent research commentary on Sight Sciences centers on refreshed models following Q1 updates and a reassessment of where the stock fits within the broader medical technology group.Narratiefupdate • Jun 02
SGHT: Dry Eye Execution And TearCare Adoption Will Support Future Upside
Analysts have maintained Sight Sciences' fair value target at $12.00 while refining underlying assumptions such as discount rate and margin forecasts. Recent Street research highlights sector models being refreshed and mixed segment trends as key drivers of the updated $5.15 Citi price target and other revised targets across the stock.Narratiefupdate • May 10
SGHT: Weaker Glaucoma Trends Will Limit Rerating Despite Solid Dry Eye Momentum
Analysts have trimmed their price targets for Sight Sciences, with one key target moving from $6.50 to $5 and another from $12 to $11. These revisions reflect updated views on a mix of steady sector fundamentals, solid Dry Eye performance, and softer Surgical Glaucoma trends.Narratiefupdate • Apr 23
SGHT: Dry Eye Franchise And TearCare Adoption Will Drive Future Upside
The blended analyst price target for Sight Sciences has moved modestly lower to $11 from $12, as analysts balance pressure in Surgical Glaucoma against steady TearCare adoption, sector wide target resets, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent research updates show a wide range of views on Sight Sciences, with price targets clustered between the mid single digits and low double digits and ratings spanning Neutral to Buy.Narratiefupdate • Apr 08
SGHT: TearCare And Dry Eye Adoption Will Support Future Upside Potential
Narrative Update on Sight Sciences Analysts have adjusted price targets for Sight Sciences into a range of $5 to $11, reflecting updated views on the balance between softer Surgical Glaucoma trends and stronger TearCare and Dry Eye performance. Overall sector fundamentals are described as healthy.Narratiefupdate • Mar 25
SGHT: Dry Eye Momentum Will Support Stronger Outlook Than Surgical Glaucoma
Analysts have trimmed their average price target on Sight Sciences by $1.00, reflecting updated assumptions around growth, margins and sector risk after recent research highlighted mixed trends between TearCare strength and softer Surgical Glaucoma performance. Analyst Commentary Street research on Sight Sciences has converged around a more cautious but still constructive stance, with price targets adjusted to reflect mixed trends between TearCare strength and softer Surgical Glaucoma performance.Narratiefupdate • Mar 11
SGHT: TearCare Momentum Will Support Rerating Despite Surgical Glaucoma Concerns
The updated analyst price target for Sight Sciences moves to $6.50, reflecting a blended view where some analysts trimmed targets, others raised them toward $8 to $11, and recent feedback on TearCare and mixed segment trends shaped modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Sight Sciences gives you a mixed picture, with some analysts more constructive on TearCare adoption and others turning more cautious on execution and growth in the surgical glaucoma segment.Narratiefupdate • Feb 24
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have maintained their $12.00 price target on Sight Sciences, noting that minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions largely offset one another. What's in the News Sight Sciences issued new earnings guidance for the fourth quarter of 2025, with total revenue expected between $20.3 million and $20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Key Developments).Narratiefupdate • Feb 09
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have kept their price target for Sight Sciences steady at US$12.00, citing updated assumptions that include slightly higher discount and P/E expectations, along with adjusted revenue growth and profit margin forecasts. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue projected between US$20.3 million and US$20.4 million.Narratiefupdate • Jan 26
SGHT: Fair Outlook Balances Guidance Revision With Leadership And Margin Assumptions
Analysts have lifted their price target for Sight Sciences from US$3.60 to US$6.00, pointing to updated assumptions around revenue growth, profit margins, discount rate and a higher future P/E multiple as key drivers of the change. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue expected between US$20.3 million and US$20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Corporate Guidance).Analyse-artikel • Jan 21
Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge Could Signal Some Risk
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has softened a substantial 26% over the previous 30 days, handing...
Narratiefupdate • Jan 11
SGHT: Final Medicare Coverage Will Support Dry Eye Upside Potential
Analysts have lifted their price target on Sight Sciences from $7.85 to $9.35, citing recent Medicare coverage decisions for the TearCare dry eye disease treatment system as a key support for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the finalized Medicare coverage policies for TearCare as a key support for the higher price targets, since clearer reimbursement can make revenue visibility easier to model.Seeking Alpha • Dec 31
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Summary Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances. SGHT faces significant liquidity risks, and I believe the company should look to raise cash in 2026, particularly in light of the recent share price surge. I see fair value near $9.50/share, but further upside depends on sales execution and additional coverage wins. Read the full article on Seeking AlphaNarratiefupdate • Dec 26
SGHT: Medicare Coverage Expansion Will Drive Stronger Outlook For Dry Eye Therapy
Analysts have raised their price target on Sight Sciences from $5 to $7 per share, citing recently finalized Medicare coverage policies for the TearCare dry eye treatment system as a key potential driver of outperformance. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in Sight Sciences' ability to monetize new Medicare coverage for its TearCare dry eye treatment system.Narratiefupdate • Dec 11
SGHT: Final Medicare Coverage Will Shape Dry Eye Outlook And Execution Risks
Analysts have modestly raised their price target on Sight Sciences from approximately $6.08 to about $7.85 per share, citing improved fair value estimates and expectations that finalized Medicare coverage for the TearCare dry eye treatment system could drive future outperformance. Analyst Commentary With the recent coverage decisions for TearCare by key Medicare administrative contractors, Street research has become more constructive on Sight Sciences' medium term outlook, though some execution risks remain in focus.Narratiefupdate • Nov 27
SGHT: Broader Medicare Coverage Will Increase Risks For Execution Going Forward
Analysts have raised their price target for Sight Sciences from $5.00 to $7.00 per share. They cite broader Medicare coverage for its Dry Eye Disease treatment system as a key factor supporting the positive outlook.Analyse-artikel • Nov 13
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narratiefupdate • Nov 08
SGHT: Higher Medicare Access Will Increase Competitive Execution Risks Ahead
Analysts have raised their price target for Sight Sciences from approximately $4.42 to $5.08, citing expanded Medicare coverage and stronger growth expectations across key financial metrics. Analyst Commentary Bullish Takeaways Bullish analysts highlighted the substantial increase in the price target following newly finalized Medicare coverage for the TearCare system.Analyse-artikel • Oct 18
Market Participants Recognise Sight Sciences, Inc.'s (NASDAQ:SGHT) Revenues Pushing Shares 37% Higher
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has done very well over the last month, posting an excellent gain...Analyse-artikel • Aug 09
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet?
NasdaqGS:SGHT 1 Year Share Price vs Fair Value Explore Sight Sciences's Fair Values from the Community and select yours...Narratiefupdate • Aug 08
Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures
Sight Sciences' consensus price target has increased, primarily reflecting improved revenue growth forecasts, with fair value rising from $3.93 to $4.27. What's in the News Raised full-year 2025 revenue guidance to $72–76 million (still a 5–10% decline vs.Analyse-artikel • May 14
Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
Sight Sciences, Inc. ( NASDAQ:SGHT ) shareholders would be excited to see that the share price has had a great month...
Nieuw narratief • Apr 04
OMNIEdge And TearCare Will Transform MIGS Treatments
Strategic initiatives, such as the OMNIEdge launch and positive reimbursement for TearCare, aim to capture market share and improve revenue and margins.Analyse-artikel • Mar 30
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough
Sight Sciences, Inc.'s ( NASDAQ:SGHT ) price-to-sales (or "P/S") ratio of 1.6x might make it look like a buy right now...Analyse-artikel • Jan 17
Is Sight Sciences (NASDAQ:SGHT) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyse-artikel • Nov 13
Sight Sciences, Inc. (NASDAQ:SGHT) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has fared very poorly over the last month, falling by a...Rendement voor aandeelhouders
| SGHT | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -2.4% | -0.7% | -1.0% |
| 1Y | 40.7% | -20.7% | 14.7% |
Rendement versus industrie: SGHT overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -20.7 % opleverde.
Rendement versus markt: SGHT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 14.7 %.
Prijsvolatiliteit
| SGHT volatility | |
|---|---|
| SGHT Average Weekly Movement | 10.7% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: SGHT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van SGHT is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2010 | 186 | Paul Badawi | www.sightsciences.com |
Sight Sciences, Inc., een oogheelkundig bedrijf voor medische hulpmiddelen, richt zich op de ontwikkeling en commercialisering van chirurgische en niet-chirurgische technologieën voor de behandeling van oogaandoeningen in de Verenigde Staten. Het bedrijf is actief in twee segmenten, chirurgisch glaucoom en droge ogen. Het biedt OMNI, een productfamilie van chirurgische systemen, zoals OMNI Ergo voor katheterisatie en transluminale viscodilatatie van het Schlemm's kanaal en het doorsnijden van het trabeculaire meshwork om de intraoculaire druk te verlagen bij volwassen patiënten met open-hoek glaucoom; en OMNI EDGE, een implantaatvrije en minimaal invasieve glaucoom chirurgie technologie.
Sight Sciences, Inc. Samenvatting
| SGHT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$267.15m |
| Inkomsten(TTM) | -US$37.25m |
| Inkomsten(TTM) | US$79.55m |
3.4x
P/S-verhouding-7.2x
Koers/WinstverhoudingIs SGHT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SGHT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$79.55m |
| Kosten van inkomsten | US$11.00m |
| Brutowinst | US$68.55m |
| Overige uitgaven | US$105.80m |
| Inkomsten | -US$37.25m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 05, 2026
| Winst per aandeel (EPS) | -0.68 |
| Brutomarge | 86.17% |
| Nettowinstmarge | -46.83% |
| Schuld/Eigen Vermogen Verhouding | 75.2% |
Hoe presteerde SGHT op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/26 10:17 |
| Aandelenkoers aan het einde van de dag | 2026/07/24 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Sight Sciences, Inc. wordt gevolgd door 10 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Craig Bijou | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |
| Frank Takkinen | Lake Street Capital Markets, LLC |